Post-Operative Cataract Surgery Inflammation Market Summary

• The Post-Operative Cataract Surgery Inflammation Market is expected to witness robust growth over the coming years, driven by an increasing number of cataract surgeries, continuous innovations in ocular drug delivery, and the entry of new therapeutic options.
• The leading Post-operative Cataract Surgery Inflammation Companies such as VivaVision Biotech Inc., Ocumension Therapeutics (Shanghai) Co. Ltd, Silverstein Eye Centers, Oculis, Bausch & Lomb Incorporated, Eyegate Pharmaceuticals Inc., Sirion Therapeutics Inc., Research Insight LLC, Alcon Research, Mati Therapeutics Inc., Kala Pharmaceuticals Inc., Biogen and others.

Post-Operative Cataract Surgery Inflammation Market & Epidemiology Analysis

• Cataracts impact approximately 95 million individuals globally, with roughly 10 million surgeries conducted each year to address them. Consequently, cataract surgery stands out as one of the most prevalent medical procedures worldwide. Postoperative inflammation frequently occurs as a complication following this surgery.
• To manage post-operative inflammation and prevent complications, patients are often prescribed topical medications, such as corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), in the form of eye drops. These medications help to suppress inflammation, reduce pain, and promote healing in the eye following surgery.
• Even with advancements in surgery, inflammation after cataract surgery persists, causing patient discomfort, slower recovery, and compromised vision. Thus, there is a pressing demand for better treatments to address these inflammatory issues and enhance surgical outcomes.
• Most recently, in March 2024, Formosa Pharmaceuticals and AimMax Therapeutics received approval from the US FDA for clobetasol propionate ophthalmic suspension 0.05%, for the treatment of post-operative inflammation and pain following ocular surgery. 
• The market for post-operative cataract surgery inflammation treatments is poised for growth due to the persistent demand for improved therapies. With advancements in technology and an aging population driving an increase in cataract surgeries, there is an opportunity for pharmaceutical companies to develop and introduce innovative solutions to address this unmet medical need.

Request for Unlocking the Sample Page of the "Post-operative Cataract Surgery Inflammation Treatment Market"

Key Factors Driving the Post-Operative Cataract Surgery Inflammation Market Growth

• Rising Incidence of Cataract Surgeries

With the growing global geriatric population and increasing cases of cataract-related vision impairment, the number of cataract surgeries has surged significantly. This rise directly contributes to a higher demand for anti-inflammatory therapies to manage post-operative complications.

• Advancements in Drug Delivery Technologies

The market is witnessing notable progress in sustained-release ocular drug delivery systems, including inserts, intracameral injections, and implants. These innovations enhance drug bioavailability, reduce dosing frequency, and improve patient compliance—driving wider adoption of advanced treatments.

• Introduction of Novel and Effective Therapies

The approval and commercialization of next-generation drugs such as Dextenza (dexamethasone ophthalmic insert) and Omidria (phenylephrine and ketorolac injection) have improved clinical outcomes and broadened therapeutic options, fueling market growth.

• Growing Awareness About Post-Surgical Care

Increasing awareness among patients and ophthalmologists regarding the importance of managing inflammation and preventing complications post-surgery has enhanced treatment uptake globally.

DelveInsight's “Post-operative Cataract Surgery Inflammation Treatment Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Post-operative Cataract Surgery Inflammation, historical and forecasted epidemiology as well as the Post-operative Cataract Surgery Inflammation market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Post-operative Cataract Surgery Inflammation Treatment Market Report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Post-operative Cataract Surgery Inflammation market size from 2020 to 2034. The report also covers current Post-operative Cataract Surgery Inflammation treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Post-operative Cataract Surgery Inflammation Disease Understanding and Treatment Algorithm

Post-operative Cataract Surgery Inflammation Overview

Cataracts, characterized by a clouding of the lens in the eye, are prevalent among the elderly and are a leading cause of blindness globally. The physical trauma endured during cataract surgery, which disrupts the blood-aqueous barrier (BAB), can trigger an inflammatory reaction. This response involves the release of inflammatory substances like prostaglandins and leukotrienes from arachidonic acid. Additionally, factors such as diabetes, the use of tamsulosin, a history of iritis, and specific surgical conditions like dense cataracts or prolonged phaco time, can heighten the risk of inflammation post-surgery.

Post-operative Cataract Surgery Inflammation Treatment

The initial inflammation following surgery is evaluated by measuring the inflammatory reaction in the front part of the eye. This inflammation is thought to stem from the surgical handling and release of lens proteins, which then trigger the release of inflammatory substances. These substances are responsible for breaking down the barrier between blood vessels and the eye, allowing white blood cells to migrate into the eye tissues. Even with advancements in surgery, inflammation following cataract surgery remains a prevalent issue, causing discomfort for patients, slowing down recovery, and impairing visual outcomes. This highlights a significant gap in the availability of effective treatments to address these inflammatory complications. 

Post-operative Cataract Surgery Inflammation Epidemiology

The Post-operative Cataract Surgery Inflammation epidemiology chapter in the report provides historical as well as forecasted data in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Post-operative Cataract Surgery Inflammation epidemiology is segmented with detailed insights into Total Diagnosed Prevalent Cases of Cataract, Total Cases of Cataract Surgery, Total Cases of Post-operative Cataract Surgery Inflammation, and Treated Cases of Post-operative Cataract Surgery Inflammation.

Key Findings from Post-Operative Cataract Surgery Inflammation Epidemiological Analysis

• According to National Eye Institute, in 2010 the prevalence of cataract was 17.11% in the US. More than half of all Americans age 80 or older either have cataracts or have had surgery to get rid of cataracts.
• As per American Academy of Ophthalmology, cataracts affect more than 24.4 million Americans age 40 and older. By age 75, approximately half of all Americans have cataracts in 2023.

Post-Operative Cataract Surgery Inflammation Epidemiology Segmentation in the 7MM

• Total Diagnosed Prevalent Cases of Cataract
• Total Cases of Cataract Surgery
• Total Cases of Post-operative Cataract Surgery Inflammation
• Treated Cases of Post-operative Cataract Surgery Inflammation

Post-operative Cataract Surgery Inflammation Drug Analysis

The drug chapter segment of the Post-operative Cataract Surgery Inflammation report encloses a detailed analysis of Post-operative Cataract Surgery Inflammation marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into the Post-operative Cataract Surgery Inflammation pivotal clinical trial details; recent and expected market approvals, patent details, the latest news, and recent deals and collaborations. 

Post-operative Cataract Surgery Inflammation Marketed Drugs

• DEXTENZA (dexamethasone ophthalmic insert): Ocular Therapeutix

DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the inner portion of the lower eyelid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives. DEXTENZA resorbs and exits the nasolacrimal system without the need for removal. The US FDA approved DEXTENZA in 2019, for the treatment of ocular inflammation and pain following ophthalmic surgery.

• INVELTYS (KPI-121 1%): Kala Bio

INVELTYS (loteprednol etabonate ophthalmic suspension) 1% is a twice-a-day corticosteroid for the treatment of inflammation and pain following ocular surgery. INVELTYS utilizes Kala’s proprietary Mucus-Penetrating Particle (MPP) technology to enhance penetration into target tissues of the eye. It was approved by the US FDA in August 2018. 

Post-operative Cataract Surgery Inflammation Emerging Drugs

• OCS-01: Oculis

Leveraging Oculis’ proprietary OPTIREACH technology, OCS-01 is a novel, high concentration (15 mg/ml), topical formulation of dexamethasone. The OPTIREACH solubilizing formulation technology addresses the main limitations of conventional eye drops by improving the solubility of lipophilic drugs, increasing the residence time on the eye surface and thereby, enabling less frequent administration for front-of-the-eye and the drug passage from the eye surface to the posterior segment for back-of-the-eye diseases. OCS-01 met both primary endpoints in the Phase III OPTIMIZE trial with a once daily regimen for the treatment of inflammation and pain following cataract surgery. Currently, the company has initiated second Phase III OPTIMIZE-2 trial for which, topline readout anticipated in the fourth quarter of 2024. If positive, the data from this trial, together with the positive results from the first Phase III OPTIMIZE-1 trial, are expected to support the NDA submission.

Post-operative Cataract Surgery Inflammation Market Outlook

Post-Operative Cataract Surgery Inflammation Companies such as Oculis, VivaVision Biotech, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of Post-operative Cataract Surgery Inflammation.

• The United States accounts for the largest Post-operative Cataract Surgery Inflammation Market Size, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
• In the coming years, continued innovation in drug development for post-operative cataract surgery inflammation is anticipated which may involve the introduction of novel drug formulations with improved efficacy, safety profiles, and convenience of administration.

Post-operative Cataract Surgery Inflammation Drugs Uptake

This section focuses on the uptake rate of potential Post-Operative Cataract Surgery Inflammation drugs expected to be launched in the market during 2024–2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake. 

Post-operative Cataract Surgery Inflammation Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key Post-Operative Cataract Surgery Inflammation Companies involved in developing targeted therapeutics. The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Post-operative Cataract Surgery Inflammation emerging therapies. 

Latest KOL-Views on Post-Operative Cataract Surgery Inflammation

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility. DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging treatment patterns of Post-operative Cataract Surgery Inflammation. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Post-Operative Cataract Surgery Inflammation Market Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival. Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Post-Operative Cataract Surgery Inflammation Market Access and Reimbursement

Reimbursement of rare disease therapies can be limited due to a lack of supporting policies and funding, challenges of high prices, lack of specific approaches to evaluating rare disease drugs given limited evidence, and payers’ concerns about budget impact. The high cost of rare disease drugs usually has a limited effect on the budget due to the small number of eligible patients being prescribed the drug. The US FDA has approved several rare disease therapies in recent years. From a patient perspective, health insurance and payer coverage guidelines surrounding rare disease treatments restrict broad access to these treatments, leaving only a small number of patients who can bypass insurance and pay for products independently. 

The Post-Operative Cataract Surgery Inflammation Therapeutics Market Report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Post-operative Cataract Surgery Inflammation Market Report

• The Post-Operative Cataract Surgery Inflammation Therapeutics Market Report covers a segment of key events, an executive summary, descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current Post-Operative Cataract Surgery Inflammation Treatment Market Landscape.
• A detailed review of the Post-operative Cataract Surgery Inflammation Treatment Market, historical and forecasted Post-Operative Cataract Surgery Inflammation Market Size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Post-Operative Cataract Surgery Inflammation Therapeutics Market Report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Post-operative Cataract Surgery Inflammation Market.

Post-operative Cataract Surgery Inflammation Market Report Insights

• Post-operative Cataract Surgery Inflammation Patient Population
• Post-operative Cataract Surgery Inflammation Therapeutic Approaches
• Post-operative Cataract Surgery Inflammation Pipeline Analysis
• Post-operative Cataract Surgery Inflammation Market Size and Trends
• Existing and future Post-Operative Cataract Surgery Inflammation Market Opportunity 

Post-operative Cataract Surgery Inflammation Market Report Key Strengths

• 11 Years Post-Operative Cataract Surgery Inflammation Market Forecast
• 7MM Coverage 
• Post-operative Cataract Surgery Inflammation Epidemiology Segmentation
• Inclusion of country-specific treatment guidelines
• KOL’s feedback on approved and emerging therapies 
• Key Cross Competition 
• Conjoint analysis
• Post-operative Cataract Surgery Inflammation Drugs Uptake
• Key Post-operative Cataract Surgery Inflammation Market Forecast Assumptions

Post-operative Cataract Surgery Inflammation Market Report Assessment

• Current Post-operative Cataract Surgery Inflammation Treatment Practices
• Post-operative Cataract Surgery Inflammation Unmet Needs
• Post-operative Cataract Surgery Inflammation Pipeline Product Profiles
• Post-operative Cataract Surgery Inflammation Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Post-operative Cataract Surgery Inflammation Market Drivers
• Post-operative Cataract Surgery Inflammation Market Barriers

Key Questions Answered in the Post-Operative Cataract Surgery Inflammation Market Report

Post-Operative Cataract Surgery Inflammation Market Insights

• What is the growth rate of the 7MM Post-operative Cataract Surgery Inflammation treatment market?
• What was the Post-operative Cataract Surgery Inflammation market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the current and emerging options for the treatment of Post-operative Cataract Surgery Inflammation? 
• How many companies are developing therapies for the treatment of Post-operative Cataract Surgery Inflammation?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies? 
• What are the country-specific accessibility issues of expensive, recently approved therapies? 

Reasons to buy Post-operative Cataract Surgery Inflammation Market Report

• The Post-Operative Cataract Surgery Inflammation Therapeutics Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Post-operative Cataract Surgery Inflammation Drugs Market.
• Insights on patient burden/disease Post-Operative Cataract Surgery Inflammation Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported Post-Operative Cataract Surgery Inflammation Sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming Post-Operative Cataract Surgery Inflammation Companies in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Post-Operative Cataract Surgery Inflammation Market so that the upcoming players can strengthen their development and launch strategy.

Stay updated with us for Recent Articles @ New DelveInsight Blogs